Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials

ABSTRACT OBJECTIVE: In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying au...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagnew, Alemnew F, Rausch, Debora, Hervé, Caroline, Zahaf, Toufik, Levin, Myron J, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937016/
https://www.ncbi.nlm.nih.gov/pubmed/32910152
http://dx.doi.org/10.1093/rheumatology/keaa424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937016/
https://www.ncbi.nlm.nih.gov/pubmed/32910152
http://dx.doi.org/10.1093/rheumatology/keaa424

Ejemplares similares